PAHC
Phibro Animal Health Corporation
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$38.24
−0.88%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.5B | 1.5B | 1.3B | 1.0B | 977.9M |
| Cost of Revenue | 1.0B | 1.0B | 896.3M | 704.6M | 679.7M |
| Gross Profit | 511.7M | 511.7M | 399.9M | 313.1M | 298.2M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 312.5M | 312.5M | 289.5M | 259.8M | 226.4M |
| General & Admin Expense | 86.2M | 312.5M | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 312.5M | 312.5M | 289.5M | 259.8M | 226.4M |
| Cost and Expenses | 1.3B | 1.3B | 1.2B | 964.4M | 906.0M |
| Operating Income (EBIT) | 198.4M | 198.4M | 110.5M | 53.3M | 71.8M |
| Non-Operating | |||||
| Interest Income | 1.5M | 1.5M | 2.6M | 4.5M | 3.4M |
| Interest Expense | 47.6M | 47.6M | 33.2M | 22.0M | 17.9M |
| Net Interest Income | (46.1M) | (46.1M) | (30.6M) | (17.5M) | (14.6M) |
| Other Non-Op Income/Expense | (61.1M) | (61.1M) | (42.5M) | (42.4M) | (17.8M) |
| Non-Operating Income (excl Interest) | 13.5M | 13.5M | 9.2M | 20.4M | (173.0K) |
| EBT (Pre-Tax Income) | 137.3M | 137.3M | 68.0M | 10.9M | 54.1M |
| Income Tax Expense | 37.6M | 37.6M | 19.7M | 8.5M | 21.5M |
| Bottom Line | |||||
| Net Income | 99.7M | 99.7M | 48.3M | 2.4M | 32.6M |
| Earnings from Cont. Ops | 99.7M | 99.7M | 48.3M | 2.4M | 32.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 99.7M | 99.7M | 48.3M | 2.4M | 32.6M |
| Per Share | |||||
| Basic EPS | $2.46 | $2.46 | $1.19 | $0.06 | $0.81 |
| Diluted EPS | $2.44 | $2.44 | $1.19 | $0.06 | $0.81 |
| Revenue Per Share | $37.39 | $37.39 | $32.01 | $25.13 | $24.14 |
| Shares | |||||
| Basic Shares Outstanding | 40.6M | 40.6M | 40.5M | 40.5M | 40.5M |
| Diluted Shares Outstanding | 41.0M | 41.0M | 40.7M | 40.5M | 40.5M |
| Profitability Metrics | |||||
| EBITDA | 236.5M | 236.5M | 146.8M | 69.1M | 106.0M |
| D&A | 51.5M | 51.5M | 45.6M | 36.2M | 34.0M |
| EBIT | 184.9M | 184.9M | 101.2M | 32.9M | 72.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026